Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phthalic Acids | 8 | 2022 | 41 | 4.560 |
Why?
|
| Postmenopause | 20 | 2025 | 246 | 4.420 |
Why?
|
| Breast Neoplasms | 24 | 2025 | 1124 | 4.320 |
Why?
|
| Environmental Pollutants | 7 | 2025 | 91 | 3.230 |
Why?
|
| Women's Health | 14 | 2022 | 390 | 2.510 |
Why?
|
| Antidepressive Agents | 5 | 2018 | 229 | 2.000 |
Why?
|
| Biomarkers | 9 | 2023 | 1198 | 1.830 |
Why?
|
| Mammography | 11 | 2019 | 272 | 1.740 |
Why?
|
| Environmental Exposure | 7 | 2025 | 205 | 1.600 |
Why?
|
| Benzhydryl Compounds | 3 | 2018 | 48 | 1.550 |
Why?
|
| Phenols | 3 | 2018 | 74 | 1.530 |
Why?
|
| Endometrial Neoplasms | 5 | 2019 | 55 | 1.350 |
Why?
|
| Endocrine Disruptors | 2 | 2021 | 74 | 1.270 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2022 | 62 | 1.140 |
Why?
|
| Prospective Studies | 25 | 2025 | 3102 | 1.130 |
Why?
|
| Female | 57 | 2025 | 30914 | 1.070 |
Why?
|
| Risk Factors | 26 | 2025 | 5014 | 1.040 |
Why?
|
| Middle Aged | 43 | 2025 | 16278 | 1.030 |
Why?
|
| Aged | 38 | 2025 | 13358 | 1.030 |
Why?
|
| Body Mass Index | 11 | 2025 | 889 | 0.960 |
Why?
|
| Case-Control Studies | 10 | 2022 | 1056 | 0.950 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 114 | 0.910 |
Why?
|
| Breast | 5 | 2022 | 173 | 0.880 |
Why?
|
| Bone Density | 3 | 2022 | 174 | 0.840 |
Why?
|
| Humans | 63 | 2025 | 59512 | 0.830 |
Why?
|
| Adiposity | 1 | 2023 | 78 | 0.800 |
Why?
|
| Sleep | 2 | 2016 | 219 | 0.750 |
Why?
|
| Depression | 3 | 2017 | 859 | 0.710 |
Why?
|
| Job Application | 2 | 2021 | 6 | 0.700 |
Why?
|
| Environmental Monitoring | 3 | 2016 | 139 | 0.690 |
Why?
|
| Menopause | 5 | 2022 | 246 | 0.690 |
Why?
|
| Suicide | 1 | 2022 | 123 | 0.680 |
Why?
|
| Osteoporotic Fractures | 3 | 2021 | 32 | 0.680 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2019 | 3 | 0.670 |
Why?
|
| Hot Flashes | 3 | 2021 | 94 | 0.670 |
Why?
|
| Medical Oncology | 2 | 2021 | 56 | 0.670 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1226 | 0.660 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 45 | 0.660 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 157 | 0.640 |
Why?
|
| United States | 19 | 2019 | 7530 | 0.640 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 83 | 0.630 |
Why?
|
| Weight Gain | 2 | 2022 | 163 | 0.630 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 2329 | 0.620 |
Why?
|
| Premenopause | 4 | 2022 | 57 | 0.620 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 2475 | 0.610 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 255 | 0.610 |
Why?
|
| Depressive Disorder | 2 | 2018 | 293 | 0.610 |
Why?
|
| Vasomotor System | 1 | 2018 | 21 | 0.600 |
Why?
|
| Sweating | 1 | 2016 | 26 | 0.540 |
Why?
|
| Cancer Survivors | 1 | 2018 | 80 | 0.540 |
Why?
|
| Incidence | 8 | 2025 | 1242 | 0.530 |
Why?
|
| Prolactin | 1 | 2016 | 40 | 0.530 |
Why?
|
| Obesity | 6 | 2025 | 1186 | 0.520 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 151 | 0.520 |
Why?
|
| Body Composition | 1 | 2016 | 154 | 0.520 |
Why?
|
| Negotiating | 1 | 2016 | 16 | 0.510 |
Why?
|
| Coffee | 2 | 2015 | 19 | 0.510 |
Why?
|
| Metabolic Syndrome | 2 | 2019 | 148 | 0.500 |
Why?
|
| Personnel Selection | 1 | 2016 | 48 | 0.490 |
Why?
|
| Research Personnel | 1 | 2016 | 86 | 0.480 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 258 | 0.480 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 162 | 0.470 |
Why?
|
| Interviews as Topic | 2 | 2016 | 490 | 0.450 |
Why?
|
| Intra-Abdominal Fat | 2 | 2025 | 34 | 0.440 |
Why?
|
| Adult | 19 | 2022 | 15776 | 0.430 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 672 | 0.410 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 645 | 0.400 |
Why?
|
| Cohort Studies | 9 | 2019 | 2443 | 0.400 |
Why?
|
| Prognosis | 4 | 2018 | 1572 | 0.390 |
Why?
|
| Melatonin | 3 | 2018 | 66 | 0.380 |
Why?
|
| Risk-Taking | 1 | 2012 | 159 | 0.380 |
Why?
|
| Caffeine | 1 | 2011 | 47 | 0.380 |
Why?
|
| Absorptiometry, Photon | 3 | 2025 | 89 | 0.370 |
Why?
|
| Densitometry | 1 | 2011 | 12 | 0.370 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 63 | 0.370 |
Why?
|
| Data Collection | 2 | 2019 | 384 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 145 | 0.360 |
Why?
|
| Creatinine | 2 | 2021 | 123 | 0.350 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 197 | 0.340 |
Why?
|
| Inflammation | 2 | 2021 | 1104 | 0.340 |
Why?
|
| Caregivers | 1 | 2012 | 218 | 0.340 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 265 | 0.330 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2021 | 86 | 0.330 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 821 | 0.310 |
Why?
|
| Breast Feeding | 2 | 2021 | 138 | 0.290 |
Why?
|
| Osteoporosis | 2 | 2013 | 138 | 0.280 |
Why?
|
| Recreation | 1 | 2007 | 22 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 200 | 0.280 |
Why?
|
| Community Pharmacy Services | 2 | 2019 | 14 | 0.270 |
Why?
|
| Hip Fractures | 1 | 2007 | 79 | 0.270 |
Why?
|
| Survivors | 1 | 2007 | 148 | 0.260 |
Why?
|
| Poverty | 2 | 2013 | 286 | 0.250 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 153 | 0.250 |
Why?
|
| Linear Models | 4 | 2015 | 422 | 0.240 |
Why?
|
| Health Education | 1 | 2006 | 184 | 0.240 |
Why?
|
| Diet | 3 | 2015 | 634 | 0.240 |
Why?
|
| Odds Ratio | 4 | 2019 | 773 | 0.240 |
Why?
|
| Fetal Blood | 1 | 2025 | 70 | 0.240 |
Why?
|
| Fluorocarbons | 1 | 2025 | 33 | 0.230 |
Why?
|
| Rural Population | 1 | 2006 | 191 | 0.230 |
Why?
|
| Subcutaneous Fat | 1 | 2025 | 47 | 0.230 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 455 | 0.230 |
Why?
|
| Motor Activity | 1 | 2007 | 343 | 0.230 |
Why?
|
| Self Report | 2 | 2016 | 367 | 0.220 |
Why?
|
| Risk Assessment | 7 | 2019 | 1915 | 0.220 |
Why?
|
| Talc | 2 | 2014 | 3 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2018 | 740 | 0.210 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 5100 | 0.200 |
Why?
|
| Autistic Disorder | 1 | 2025 | 169 | 0.200 |
Why?
|
| Health Promotion | 1 | 2006 | 490 | 0.200 |
Why?
|
| Pregnancy | 5 | 2025 | 2355 | 0.190 |
Why?
|
| Pelvic Bones | 1 | 2021 | 7 | 0.190 |
Why?
|
| Femur Neck | 1 | 2021 | 18 | 0.190 |
Why?
|
| Autism Spectrum Disorder | 1 | 2025 | 179 | 0.190 |
Why?
|
| Parity | 1 | 2021 | 71 | 0.190 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2021 | 59 | 0.180 |
Why?
|
| Surveys and Questionnaires | 6 | 2015 | 2591 | 0.180 |
Why?
|
| Logistic Models | 3 | 2016 | 1251 | 0.180 |
Why?
|
| Pharmacists | 2 | 2019 | 124 | 0.170 |
Why?
|
| Culture | 2 | 2018 | 76 | 0.160 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 25 | 0.160 |
Why?
|
| Pharmacies | 1 | 2019 | 36 | 0.160 |
Why?
|
| Anthropometry | 2 | 2009 | 80 | 0.160 |
Why?
|
| Body Weight | 2 | 2011 | 380 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2021 | 203 | 0.150 |
Why?
|
| Women | 1 | 2018 | 46 | 0.150 |
Why?
|
| Young Adult | 4 | 2016 | 4326 | 0.150 |
Why?
|
| Mastectomy | 1 | 2018 | 52 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 197 | 0.150 |
Why?
|
| Mammary Glands, Human | 2 | 2015 | 50 | 0.150 |
Why?
|
| Ovariectomy | 1 | 2018 | 97 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 135 | 0.150 |
Why?
|
| Maternal Behavior | 1 | 2018 | 31 | 0.150 |
Why?
|
| Time Factors | 5 | 2018 | 3583 | 0.140 |
Why?
|
| Child | 3 | 2025 | 4313 | 0.140 |
Why?
|
| Adolescent | 5 | 2023 | 5922 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 454 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 352 | 0.130 |
Why?
|
| Mortality | 1 | 2017 | 161 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2018 | 282 | 0.130 |
Why?
|
| Costs and Cost Analysis | 2 | 2007 | 99 | 0.130 |
Why?
|
| Hypertension | 2 | 2019 | 600 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 373 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2018 | 521 | 0.120 |
Why?
|
| Tea | 1 | 2015 | 26 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 306 | 0.120 |
Why?
|
| Perineum | 1 | 2014 | 18 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 2040 | 0.120 |
Why?
|
| Fatty Acids, Essential | 1 | 2013 | 8 | 0.110 |
Why?
|
| Folic Acid | 1 | 2014 | 58 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2016 | 330 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2014 | 63 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 135 | 0.110 |
Why?
|
| Health Services Accessibility | 3 | 2008 | 541 | 0.110 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2013 | 9 | 0.110 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 925 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 313 | 0.100 |
Why?
|
| Male | 7 | 2025 | 27582 | 0.100 |
Why?
|
| Age Factors | 2 | 2014 | 1516 | 0.100 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2012 | 48 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2012 | 52 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2013 | 48 | 0.100 |
Why?
|
| Time | 1 | 2012 | 27 | 0.100 |
Why?
|
| Physical Examination | 1 | 2012 | 103 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2013 | 193 | 0.100 |
Why?
|
| Health Literacy | 1 | 2013 | 77 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2013 | 154 | 0.100 |
Why?
|
| Smoking | 2 | 2007 | 829 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 446 | 0.100 |
Why?
|
| Melanoma | 1 | 2015 | 334 | 0.100 |
Why?
|
| Diet Surveys | 1 | 2011 | 78 | 0.090 |
Why?
|
| Waist-Hip Ratio | 1 | 2011 | 12 | 0.090 |
Why?
|
| Soybean Proteins | 1 | 2011 | 16 | 0.090 |
Why?
|
| Minority Groups | 2 | 2013 | 140 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 83 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 405 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1554 | 0.090 |
Why?
|
| North Carolina | 2 | 2007 | 66 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 167 | 0.080 |
Why?
|
| Asthma | 1 | 2014 | 419 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2010 | 309 | 0.080 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 16 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 30 | 0.080 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2008 | 78 | 0.080 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 30 | 0.080 |
Why?
|
| Testosterone | 1 | 2008 | 111 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 705 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 138 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 582 | 0.070 |
Why?
|
| Estradiol | 1 | 2008 | 242 | 0.070 |
Why?
|
| Body Height | 1 | 2007 | 75 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 261 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2008 | 146 | 0.070 |
Why?
|
| Mass Screening | 2 | 2008 | 649 | 0.070 |
Why?
|
| Patient Selection | 1 | 2008 | 447 | 0.060 |
Why?
|
| Colonic Polyps | 1 | 2005 | 26 | 0.060 |
Why?
|
| Singapore | 1 | 2025 | 10 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2005 | 72 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 790 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2005 | 98 | 0.060 |
Why?
|
| Breast Density | 2 | 2015 | 16 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 783 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 448 | 0.050 |
Why?
|
| Amygdala | 1 | 2023 | 80 | 0.050 |
Why?
|
| Pain | 1 | 2023 | 405 | 0.040 |
Why?
|
| Career Choice | 1 | 2021 | 111 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6013 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2019 | 53 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2019 | 34 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2021 | 250 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2018 | 59 | 0.040 |
Why?
|
| Cause of Death | 1 | 2017 | 199 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 5180 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 144 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 34 | 0.030 |
Why?
|
| Powders | 1 | 2014 | 19 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1286 | 0.030 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 22 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 60 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2014 | 40 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1306 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1090 | 0.030 |
Why?
|
| Minority Health | 1 | 2013 | 6 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 1524 | 0.030 |
Why?
|
| Cities | 1 | 2013 | 25 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 43 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 17 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 36 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2013 | 31 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 164 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 182 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 122 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2014 | 249 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 143 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2008 | 46 | 0.020 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2007 | 57 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2007 | 16 | 0.020 |
Why?
|
| Indians, North American | 1 | 2007 | 26 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 243 | 0.020 |
Why?
|
| Smoking Prevention | 1 | 2007 | 162 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 2007 | 98 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 401 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 215 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 36 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2005 | 85 | 0.020 |
Why?
|
| Adenoma | 1 | 2005 | 63 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2005 | 103 | 0.020 |
Why?
|
| Perception | 1 | 2005 | 179 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 577 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2007 | 531 | 0.010 |
Why?
|